Clinical Trial Update: Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing anti-VEGF therapy alone versus Ozurdex (dexamethasone intravitreal implant) given every 3 months for persistent diabetic macular edema…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Ozurdex (dexamethasone intravitreal implant)
• anti-VEGF therapy

Snippet

Sponsor: Raj K. Maturi, MD | Conditions: Diabetic Macular Edema | Phase 4 | Status: COMPLETED | Results posted: 2015-11-03